Please provide your email address to receive an email when new articles are posted on . The study included 72 individuals with ischemic stroke given alteplase and tenecteplase. No significant time ...

Tenecteplase given 4.5-24 hours post-stroke does not boost functional outcomes in patients with occlusions of the internal carotid artery or M1 or M2 segments of the middle cerebral artery who showed ...

Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...

SOUTH SAN FRANCISCO, Calif., March 03, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has ...

Making the switch from alteplase to tenecteplase for stroke thrombolysis can be done successfully when the appropriate preparations are taken, and it may improve patient outcomes, the experience of a ...

CNW/ - Hoffmann-La Roche Limited (Roche Canada) is proud to announce that Health Canada has granted market authorization for ...

TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in ...

Whether the evidence supports wider use of tenecteplase (TNKase; Genentech)—a thrombolytic agent with an indication for acute MI—as an alternative to alteplase (Activase; Genentech) for the treatment ...

On Dec. 3, Swiss pharmaceutical company Roche's independent subsidiary Genentech announced that its thrombolytic agent "TNKase (tenecteplase)" has received FDA approval as a treatment for adult acute ...

THURSDAY, March 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic ...